Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K. Blauvelt A, et al. Among authors: mendelsohn a. J Eur Acad Dermatol Venereol. 2019 Dec;33(12):2305-2312. doi: 10.1111/jdv.15862. Epub 2019 Sep 11. J Eur Acad Dermatol Venereol. 2019. PMID: 31407394 Free PMC article.
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
Poulin Y, Ramon M, Rosoph L, Weisman J, Mendelsohn AM, Parno J, Rozzo SJ, Lee P. Poulin Y, et al. Among authors: mendelsohn am. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1500-1509. doi: 10.1111/jdv.16187. Epub 2020 Feb 9. J Eur Acad Dermatol Venereol. 2020. PMID: 31919889 Clinical Trial.
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
Gordon KB, Reich K, Crowley JJ, Korman NJ, Murphy FT, Poulin Y, Spelman L, Yamauchi PS, Mendelsohn AM, Parno J, Rozzo SJ, Ellis CN. Gordon KB, et al. Among authors: mendelsohn am. J Dermatolog Treat. 2022 Feb;33(1):219-228. doi: 10.1080/09546634.2020.1747590. Epub 2020 Apr 30. J Dermatolog Treat. 2022. PMID: 32349565 Free article. Clinical Trial.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K. Thaci D, et al. Among authors: mendelsohn am. Br J Dermatol. 2021 Aug;185(2):323-334. doi: 10.1111/bjd.19866. Epub 2021 May 4. Br J Dermatol. 2021. PMID: 33544883 Clinical Trial.
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi CL, Gooderham M, Gebauer K, Tada Y, Lacour JP, Bianchi L, Egeberg A, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Mehta NN. Fernandez AP, et al. Among authors: mendelsohn am. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1774-1783. doi: 10.1111/jdv.18167. Epub 2022 Jun 25. J Eur Acad Dermatol Venereol. 2022. PMID: 35460287 Free PMC article. Clinical Trial.
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter A. Lebwohl MG, et al. Among authors: mendelsohn am. J Am Acad Dermatol. 2020 Feb;82(2):519-522. doi: 10.1016/j.jaad.2019.09.042. Epub 2019 Sep 26. J Am Acad Dermatol. 2020. PMID: 31563641 Free article. No abstract available.
544 results